清华程京院士课题组采用我司硅羧基磁珠PMSi300003提取咽拭子检测新冠

Sensitive and Rapid Diagnosis of Respiratory Virus Coinfection Using a Microfluidic Chip-Powered CRISPR/Cas12a System

使用微流控芯片驱动的 CRISPR/Cas12a 系统灵敏快速地诊断呼吸道病毒感染
Jiajia Liu,Huili Wang,Li Zhang,Ying Lu,Xu Wang,Minjie Shen,Nan Li,Li Feng,Juhui Jing,Bin Cao,Xiaohui Zou,Jing Cheng,Youchun Xu
First published: 22 May 2022 https://doi.org/10.1002/smll.202200854


Abstract
The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 is profoundly influencing the global healthcare system and people's daily lives. The high resource consumption of coronavirus disease 2019 (COVID-19) is resulting in insufficient surveillance of coinfection or resurgence of other critical respiratory epidemics, which is of public concern. To facilitate evaluation of the current coinfection situation, a microfluidic system (MAPnavi) is developed for the rapid (<40 min) and sensitive diagnosis of multiple respiratory viruses from swab samples in a fully sealed and automated manner, in which a nested-recombinase polymerase amplification and the CRISPR-based amplification system is first proposed to ensure the sensitivity and specificity. This novel system has a remarkably low limit of detection (50–200 copies mL−1) and is successfully applied to detect 171 clinical samples (98.5% positive predictive agreement; 100% negative predictive agreement), and the results identify 45.6% coinfection among clinical samples from patients with COVID-19. This approach has the potential to shift diagnostic and surveillance efforts from targeted testing for a high-priority virus to comprehensive testing of multiple virus sets and to greatly benefit the implementation of decentralized testing.

摘要 

      由严重急性呼吸综合征冠状病毒 2 引起的持续大流行正在深刻影响全球医疗保健系统和人们的日常生活。 2019 年冠状病毒病 (COVID-19) 的高资源消耗导致对合并感染或其他严重呼吸道传染病复发的监测不足，这是公众关注的问题。为了便于评估当前的共感染情况，开发了一种微流控系统 (MAPnavi)，用于以完全密封和自动化的方式快速（<40 min）和灵敏地诊断拭子样本中的多种呼吸道病毒，其中嵌套重组酶聚合酶首次提出了基于CRISPR的扩增系统，以确保灵敏度和特异性。这种新型系统具有非常低的检测限（50-200 拷贝 mL-1），并成功应用于检测 171 个临床样本（98.5% 的阳性预测一致性；100% 的阴性预测一致性），结果确定了 45.6% 的共感染来自 COVID-19 患者的临床样本。这种方法有可能将诊断和监测工作从针对高优先级病毒的针对性测试转变为对多个病毒集的全面测试，并极大地有利于分散测试的实施。

本论文所采用的磁珠：http://www.purimagbead.com/Product/267584288.html